Health
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications.
About this update from Renalytix Plc
[{"type":"text","content":"The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers","length":259,"tagName":"p"},{"type":"text","content":"NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications.","length":515,"tagName":"p"},{"type":"image","alt":"Renalytix plc (PRNewsfoto/Renalytix plc)","displaySize":"","headline":null,"caption":"Renalytix plc (PRNewsfoto/Renalytix plc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":163,"url":"https://media.zenfs.com/en/prnewswire.com/cd4b47f5a3572d110efdddaf25f72e5d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c_20eVQQLDnJhM_CKAdo8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4Nw--/https://media.zenfs.com/en/prnewswire.com/cd4b47f5a3572d110efdddaf25f72e5d","width":400,"height":163},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/nuTlqUQDHswGghP7eenZ_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2MQ--/https://media.zenfs.com/en/prnewswire.com/cd4b47f5a3572d110efdddaf25f72e5d","width":400,"height":163}},"href":"https://mma.prnewswire.com/media/2562585/Renalytix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"By integrating Renalytix's FDA-approved kidneyintelX.dkd test, the gold standard in predicting progressive decline in kidney function in patients with type 2 diabetes and early-stage CKD, with Carna Health's AI-driven prevention and digital care management platform, health systems can benefit from moving beyond traditional detection to risk-guided, personalized care pathways that enable earlier, targeted interventions before patients reach catastrophic, high-cost clinical milestones.","length":501,"tagName":"p"},{"type":"text","content":"With Medicare spending on CKD exceeding $130 bil...